Brilliant Blue G Ophthalmic Solution


Brilliant Blue G Ophthalmic Solution

Drug updated on 4/18/2024

Dosage FormInjection (intraocular: 0.025%)
Drug ClassDisclosing agents
Ongoing and
Completed Studies


  • Indicated to selectively stain the internal limiting membrane (ILM).

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Brilliant Blue G Ophthalmic Solution (TissueBlue) is indicated for the selective staining of the internal limiting membrane (ILM). It has been found to be more effective than indocyanine green (ICG) in improving postoperative best-corrected visual acuity and primary macular hole closure rates, with a higher safety profile.
  • Four systematic reviews/meta-analyses compared the efficacy and safety of TissueBlue to other chromovitrectomy dyes such as ICG, trypan blue (TB), and triamcinolone acetonide (TA).
  • Comparisons of TissueBlue with TB showed promising outcomes in the closure rates of idiopathic macular holes (IMH) and in improving postoperative visual acuity. Initial analyses suggest that TissueBlue provides comparable or slightly superior effectiveness while maintaining a good safety profile.
  • Compared to TA, TissueBlue was ranked highest or nearly highest for postoperative BCVA (Best Corrected Visual Acuity) improvements and macular hole closure rates, indicating its superiority over TA in terms of overall efficacy.
  • The studies covered a wide range of IMH stages (II - IV). Certain studies emphasized the technique of applying these dyes, which could influence their comparative effectiveness. This suggests broad applicability but also indicates that further research might be needed on how the use of TissueBlue can optimize outcomes within specific patient subgroups.
  • The duration of follow-up varied across studies from 3 months up to 12 months, suggesting that long-term safety and efficacy considerations are essential.